Rybelsus (semaglutide) is an oral glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for treating type 2 diabetes mellitus in adults. Whilst effective in improving glycaemic control, Rybelsus can cause diarrhoea as a recognised side effect. This gastrointestinal symptom is directly related to the medication's mechanism of action on gut motility and secretion. Understanding the frequency, causes, and management strategies for diarrhoea associated with Rybelsus enables patients and healthcare professionals to anticipate and address this common adverse reaction appropriately, ensuring optimal treatment outcomes and quality of life.

Can Rybelsus Cause Diarrhoea?

Yes, Rybelsus (semaglutide) can cause diarrhoea as a recognised side effect. Rybelsus is an oral glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus in adults. It works by mimicking the action of the naturally occurring hormone GLP-1, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, and slows gastric emptying.

The gastrointestinal effects of Rybelsus are directly related to its mechanism of action. GLP-1 pathways influence gut motility and secretion via enteric and central mechanisms. When semaglutide binds to these receptors, it can alter normal digestive processes, leading to various gastrointestinal symptoms including diarrhoea, nausea, vomiting, and abdominal discomfort.

Clinical trial data submitted to the Medicines and Healthcare products Regulatory Authority (MHRA) and European Medicines Agency (EMA) consistently demonstrate that diarrhoea is among the most frequently reported adverse reactions to Rybelsus. The Summary of Product Characteristics (SmPC) for Rybelsus lists diarrhoea as a 'very common' side effect, occurring in more than 1 in 10 patients. This classification reflects the substantial proportion of individuals who experience loose or watery stools during treatment.

It is important to note that whilst diarrhoea is a recognised adverse effect, the severity and duration vary considerably between individuals. Most cases are mild to moderate in intensity and tend to improve over time as the body adjusts to the medication. Understanding this connection helps patients and healthcare professionals anticipate and manage this side effect appropriately.

How Common Is Diarrhoea with Rybelsus?

Diarrhoea is classified as a 'very common' side effect of Rybelsus, occurring in more than 1 in 10 patients according to the UK Summary of Product Characteristics. The incidence varies by dose, with higher rates observed at the maintenance doses of 7 mg and 14 mg compared to the initial 3 mg dose.

In the PIONEER clinical trial programme, which evaluated the efficacy and safety of oral semaglutide across diverse patient populations, diarrhoea was consistently reported across all studies. The frequency was highest during the dose-escalation phase, particularly in the first 4–8 weeks of treatment. Most episodes were transient, with the majority resolving within several weeks without requiring treatment discontinuation. Severe cases leading to dehydration or electrolyte disturbances can occur but are less common.

Several factors may potentially influence an individual's experience of diarrhoea whilst taking Rybelsus:

• Dose escalation speed: Rapid increases in dose may increase gastrointestinal side effects

• Concomitant medications: Other drugs affecting gut motility or secretion may contribute to symptoms

• Dietary factors: Food choices may interact with the medication's effects on gastric emptying

• Individual sensitivity: Some patients may be more susceptible to gastrointestinal effects

The risk of diarrhoea typically diminishes with continued treatment. Long-term safety data suggest that gastrointestinal side effects, including diarrhoea, tend to decrease in frequency and severity after the first three months of therapy. This adaptation period reflects physiological adjustment to the medication's effects on the gastrointestinal system.

Managing Diarrhoea While Taking Rybelsus

Effective management of diarrhoea whilst taking Rybelsus involves both preventative strategies and symptomatic treatment. The National Institute for Health and Care Excellence (NICE) emphasises the importance of patient education regarding potential side effects before initiating GLP-1 receptor agonist therapy, enabling individuals to recognise and respond appropriately to gastrointestinal symptoms.

Dietary modifications can significantly reduce the severity of diarrhoea:

• Adopt a low-fat diet, as high-fat meals may exacerbate gastrointestinal symptoms

• Avoid spicy, heavily seasoned, or irritating foods

• Reduce caffeine and alcohol intake, both of which can stimulate bowel activity

• Eat smaller, more frequent meals rather than large portions

• Ensure adequate fibre intake from soluble sources (oats, bananas) which can help bulk stools

• Temporarily limit dairy products if lactose intolerance is suspected

Hydration is paramount when experiencing diarrhoea. Patients should take frequent small sips of water or oral rehydration solutions to compensate for fluid losses. Aim for pale-coloured urine as a sign of adequate hydration. People with heart, kidney or liver disease should seek specific advice from their healthcare professional about appropriate fluid intake.

Medication adherence and timing also play important roles. Rybelsus should be taken exactly as prescribed—on an empty stomach with no more than 120 ml of water, at least 30 minutes before food, drink, or other medications. Proper administration optimises absorption and may reduce gastrointestinal side effects.

Over-the-counter antidiarrhoeal medications such as loperamide may provide symptomatic relief for mild to moderate diarrhoea. However, patients should consult their GP or pharmacist before using these preparations, and they should not be used if there is blood in the stool, high fever, or severe abdominal pain. Some patients find probiotics helpful, though evidence for their efficacy specifically with GLP-1 receptor agonist-induced diarrhoea is limited.

If diarrhoea persists beyond the initial adjustment period or significantly impacts quality of life, patients should consult their healthcare professional. Do not change or stop taking Rybelsus without speaking to your prescriber first.

Patients are encouraged to report any suspected side effects to the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

When to Seek Medical Advice About Digestive Side Effects

Whilst mild diarrhoea is expected with Rybelsus, certain symptoms warrant prompt medical evaluation. Patients should contact their GP or diabetes specialist nurse if they experience any of the following:

• Severe or persistent diarrhoea lasting more than 48 hours despite conservative management

• Signs of dehydration: excessive thirst, dark urine, dizziness, reduced urine output, dry mouth, or confusion

• Blood in stools or black, tarry stools suggesting gastrointestinal bleeding

• Severe abdominal pain, particularly if persistent or worsening

• Fever accompanying diarrhoea, which may indicate infection

• Unintentional weight loss beyond expected therapeutic effects

• Inability to maintain adequate oral intake of food or fluids

Patients should seek urgent medical attention (via NHS 111 or emergency services) if they develop symptoms suggesting serious complications, including severe dehydration with altered consciousness, persistent vomiting preventing oral intake, or signs of acute pancreatitis. If pancreatitis is suspected (severe persistent upper abdominal pain, sometimes radiating to the back, with or without vomiting), stop taking semaglutide and seek urgent medical advice.

For individuals with pre-existing renal impairment, diarrhoea poses additional risks. Dehydration and volume depletion can precipitate acute kidney injury, particularly in those taking concomitant medications such as ACE inhibitors, diuretics, or NSAIDs. These patients require closer monitoring and should have a lower threshold for seeking medical advice.

Healthcare professionals should conduct a thorough assessment when patients report problematic diarrhoea. This includes evaluating hydration status, reviewing concomitant medications, excluding alternative causes (such as infection or coeliac disease), and checking renal function and electrolytes if clinically indicated. Depending on severity and impact on quality of life, management options include dose reduction, temporary treatment interruption, or switching to an alternative glucose-lowering therapy.

Regular follow-up is essential during Rybelsus therapy. NICE guidance recommends a review at around 6 months to assess benefit and tolerability; treatment should continue only if there is a beneficial response. Patients should be encouraged to maintain open communication with their diabetes care team regarding any concerns about side effects, enabling timely intervention and optimisation of treatment.

Frequently Asked Questions